RYTM RHYTHM PHARMACEUTICALS, INC. Insider Trading

Director Lynn A. Tetrault sold 37,000 RYTM shares at $100.32 (2026-06-22) via pre-arranged 10b5-1 plan; retains 7,000 shares post-sale.

Lynn A. Tetrault, a director, executed a scheduled sale of 37,000 shares for $3,711,895.50 under a 10b5-1 trading plan adopted on 2025-12-15. The sale reduced his non-derivative holdings from 44,000 shares to 7,000 shares. Prior sales at RYTM have shown a pattern of negative 30-day returns (ranging from -2.2% to -5.2%) followed by positive 90-day performance (ranging from +13.5% to +17.7%). The stock is trading at $107.55, down -12.0% from its 52-week high of $122.20, though it has gained +22.4% over the past 30 days and +31.3% over 90 days. The company generated $60,112,000.00 in revenue last quarter but remains unprofitable with a net loss of $-55,639,000.00, though annual revenue growth reached +45.8%. Because this sale is pre-arranged and not discretionary, it reflects scheduling compliance rather than discretionary timing decisions.

Corporate Controller of RYTM sold 5,614 shares (97.2% of holdings) at $89.56; stock now -20.5% from 52-week high despite +45.8% revenue growth.

Corporate Controller Christopher Paul executed a large reduction of his stake, selling 5,614 shares and leaving just 160 shares post-transaction. The timing is notable given the company's recent price decline of -13.4% over 30 days and -10.6% over 90 days, bringing the stock to -20.5% below its 52-week high of $117.62. The company reported strong annual revenue growth of +45.8% and current-quarter revenue of $51.3M, but remains unprofitable with a full-year net income of $-52.9M and latest quarterly losses of $-52.9M. This near-complete liquidation by a C-suite financial officer—retaining only 160 shares of a $6.4B market-cap company—during a period of stock weakness and persistent operating losses warrants close monitoring of the company's financial trajectory and cash position.

CFO Smith Hunter C sold 7,954 shares at blended $101.31 on 2026-02-17 & 2026-02-19 for $805,813.77.

Smith Hunter C, CFO of Rhythm Pharmaceuticals, executed 9 separate sales totaling 7,954 shares for $805,813.77 across two trading days (2026-02-17 and 2026-02-19), reducing his holdings from 118,466 to 110,512 shares (-6.7%). The transactions occurred at prices ranging from $99.42 to $103.84, near current levels ($103.16), with the blended average at $101.31. The company is currently unprofitable (net income $-52.9M in the latest full fiscal year) despite strong revenue growth of +68.1%, and the stock is -12.3% from its 52-week high of $117.62. His cross-ticker track record shows 20 prior sells with an average 90-day return of +26.3%, indicating his prior sells were generally followed by stock appreciation—a poorly-timed pattern. The multiple transactions and absence of FLAG annotations suggest these were discretionary sales rather than part of a structured 10b5-1 plan.

CFO Smith Hunter C sold 7,071 shares across 10 transactions (Feb 10-12) at avg $100.21; stock now $96.06.

Smith Hunter C, CFO of Rhythm Pharmaceuticals, executed 10 separate sales totaling 7,071 shares for $708,575.59 across three trading days (Feb 10-12, 2026), with a blended average price of $100.21. Post-transaction holdings stand at 118,466 shares, a 5.6% reduction. The sales occurred as the stock has declined 10.9% over 30 days and 18.3% from its 52-week high of $117.62, now trading at $96.06—below the blended transaction price. His cross-ticker track record shows prior sells with an average 90-day return of +25.6%, though at this specific ticker (RYTM), measurable outcomes are limited, with only 1 prior sale showing a 90-day outcome (+4.0% return). The company remains unprofitable (net income $-52.9M in the latest full year) despite strong revenue growth of 68.1%, adding context to insider liquidity activity at a unprofitable, growth-stage biotech.

CFO Smith Hunter C sells 6,628 shares at $106.03 avg for $702.7K; current price $103.61 is -11.9% from 52-week high

Smith Hunter C, CFO of Rhythm Pharmaceuticals, executed 4 separate sales totaling 6,628 shares for $702,744.15 on 2026-02-04 and 2026-02-05, reducing holdings by 5.0% to 125,537 shares. The sales occurred at an average price of $106.03, which is 2.3% above the current price of $103.61 and within the 52-week trading range. Across his 5 prior sales at RYTM, the insider's timing track record shows 0 of 5 sales were well-timed at the 90-day mark (mean 90-day return +11.4%), indicating the insider has not consistently sold before downturns at this ticker. The company is currently unprofitable (net income $-52.9M) but growing revenue at +68.1% annually, creating a risk/reward context typical of high-growth biotech.

CHRO Pamela Cramer sold 22,866 shares (22.9K) across 2 transactions for $2,263,825.81 ($2.3M) at blended $99.00, reducing holdings 52.3%

Pamela Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, executed 2 separate sales totaling 22,866 shares for $2,263,825.81, reducing her holdings from 43,680 shares to 20,814 shares (a 52.3% reduction). The company is unprofitable with net income of $-52,904,000.00 against revenue of $51,298,000.00 for the latest quarter, though it showed strong annual revenue growth of 68.1%. Notably, Cramer's prior 5 sales at this ticker all resulted in positive 90-day returns, indicating the stock rose after she sold; none of those prior trades were well-timed at the 90-day mark. This filing reflects a substantial liquidation of her position; investors should monitor whether the stock's current price of $97.92 (14.0% below the 52-week high) represents value or signals continued headwinds at an unprofitable but fast-growing company.

CTO Joseph Shulman sold 9,748 shares of RYTM at $115.24 (Oct 30), reducing stake by 53.4% to 8,509 shares; stock up 14.9% in 30 days.

Joseph Shulman, Chief Technical Officer, executed a substantial sale reducing his RYTM holdings by 53.4%, divesting 9,748 shares at $115.24 on a stock trading near its 52-week high of $113.89 and up 14.9% over the prior 30 days. His cross-ticker track record shows 10 prior sells with a 90d well-timed rate of 100.00%, though this represents sales that preceded stock declines; however, same-ticker history at RYTM is mixed—only 1 of measurable sales outcomes was well-timed at the 90-day mark, and the most recent prior sale (2025-10-16) outcome is not yet measurable. The company is scaling revenue (+68.1% annual growth) but remains unprofitable ($-46.6M net income on $48.5M quarterly revenue), creating a fundamental risk profile that may warrant scrutiny of insider positioning during periods of strong momentum.

CTO Joseph Shulman sells 14,437 shares (62.9% reduction) for $1,617,336.81 at $112.03 blended average

Joseph Shulman, Chief Technical Officer, executed 3 separate sales on 2025-10-16 totaling 14,437 shares for $1,617,336.81, reducing his holdings from 22,946 to 8,509 shares—a 62.9% reduction in position size at a blended average price of $112.03. The current stock price of $112.39 is at the 52-week high, and the company has demonstrated strong recent momentum (+17.0% over 30 days, +28.0% over 90 days) despite being unprofitable with a quarterly net loss of $46,632,000.00. Notably, Shulman's prior 4 measurable sells at RYTM were all well-timed at the 90-day mark (stock fell after each sale), and his broader cross-ticker track record shows a 100.00% well-timed rate on 7 prior sells with an average 90-day return of -22.7%, establishing a consistent pattern of selling into strength before subsequent declines. This substantial liquidation at the stock's 52-week high, combined with his demonstrated ability to time exits, warrants attention in the context of the company's unprofitable status and elevated valuation.

CTO Shulman Joseph sold 16,781 shares (66.4% of holdings) at $105.30 for $1.8M; prior 5 RYTM sales all declined 90-days post-trade.

Joseph Shulman, Chief Technical Officer, executed a substantial open-market sale of 16,781 shares at $105.30 on 2025-09-02, reducing his position from 25,290 to 8,509 shares and realizing $1.8M in proceeds. The timing signal is notable: his five prior sales at RHYTHM over early 2024 all resulted in negative 90-day returns, with a consistent pattern of declines ranging from -13.1% to -23.8%. His cross-ticker track record shows a 100.00% well-timed sell rate across 6 prior sales (average 90d return -22.7%), suggesting a demonstrated ability to sell ahead of downside. The stock currently trades at $104.57, only 0.0% below its 52-week high, having surged +18.1% in 30 days and +53.5% in 90 days—a peak from which an insider with a consistent track record of identifying sell windows may perceive elevated risk. The company remains unprofitable on an annual basis despite +68.1% revenue growth, and Joseph has now divested two-thirds of his remaining stake at what appears to be a tactical inflection point.

CFO Smith Hunter C sold 28,088 shares for $2,704,623.77 near 52-week high; stock up 61.0% in 90 days

Smith Hunter C (Chief Financial Officer) sold 24,611 shares at $96.33 on 2025-08-12 and 3,477 shares at $96.00 on 2025-08-13, totaling 28,088 shares for $2,704,623.77 at a blended average price of $96.29. The sales occurred near the stock's 52-week high of $97.86 (−1.4% from peak), following a 90-day rally of +61.0% and 30-day gain of +8.0%. The CFO reduced his holdings by 19.4%, from 145,003 shares to 116,915 shares post-transaction. Underlying company fundamentals show significant disparities: the latest quarter generated $48,502,000.00 in revenue with a net loss of −$46,632,000.00, though annual revenue growth reached +68.1% year-over-year. His prior five sales at RYTM all occurred within the last three months (July and May 2025), and his cross-ticker track record across eight prior open-market sales shows a 0.00% well-timed rate at the 90-day mark (average 90d return +9.4%), indicating that past sales have not preceded price declines. The timing context—sales near an all-time high after a sustained rally—contrasts sharply with the company's ongoing unprofitability, warranting attention to whether this represents a deliberate capital reallocation or a discrete portfolio adjustment.